Alpha Bioventure
Bispecific antibody development technology platform and anti-cancer antibody drugs
Alpha Bioventure has launched a bispecific antibody technology platform in Princeton, New Jersey, trying to promote the clinical development of antibody drugs. We cooperate with entrepreneurs who have successful entrepreneurial experience in anti-cancer drugs discovery.
A project for nasal diseases founded in Pennsylvania is now in stable progress. We make use of nasal immunization technology to accelerate the discovery process of nasal medicine.
Alpha Bioventure is recruiting fund projects, and you can see details through our Join Us page.
Email:
We welcome any feedback and will respond to your questions, suggestions or comments wherever possible.